ScholarIQanswers from OpenAlex & ORCID
Anita Giobbie‐Hurder
ResearcherPublications, citations & collaboration network
Anita Giobbie‐Hurder is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Anita Giobbie‐Hurder have?
ScholarIQindexed works
Anita Giobbie‐Hurder has 693 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Anita Giobbie‐Hurder have?
ScholarIQcitation count
Anita Giobbie‐Hurder has 26,408 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Anita Giobbie‐Hurder?
ScholarIQh-index
Anita Giobbie‐Hurder has an h-index of 74 in OpenAlex.
What is the i10-index of Anita Giobbie‐Hurder?
ScholarIQi10-index
Anita Giobbie‐Hurder has an i10-index of 189 in OpenAlex.
What is the ORCID of Anita Giobbie‐Hurder?
ScholarIQorcid
The ORCID for Anita Giobbie‐Hurder is on the source record.
What is the OpenAlex record for Anita Giobbie‐Hurder?
ScholarIQopenalex
The OpenAlex for Anita Giobbie‐Hurder is on the source record.
What are the most-cited papers on Anita Giobbie‐Hurder?
ScholarIQmost cited works
Open Mesh versus Laparoscopic Mesh Repair of Inguinal Hernia
Leigh Neumayer, Anita Giobbie‐Hurder, Olga Jonasson, Robert Fitzgibbons, Dorothy D. Dunlop, James O. Gibbs, Domenic J. Reda, William G. Henderson
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
Mizuki Nishino, Anita Giobbie‐Hurder, Hiroto Hatabu, Nikhil H. Ramaiya, F. Stephen Hodi
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino, Anita Giobbie‐Hurder, Maria Gargano, Margaret Suda, Nikhil H. Ramaiya, F. Stephen Hodi
Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial.
Robert J Fitzgibbons, Anita Giobbie‐Hurder, James O. Gibbs, Dorothy D. Dunlop, Domenic J. Reda, Martin McCarthy, Leigh Neumayer, Jeffrey Barkun, James L. Hoehn, Joseph Murphy, George A. Sarosi, William C. Syme, Jon S. Thompson, Jia Wang, Olga Jonasson
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier